In two independent clinical cohorts, the ratio of CD8+ T cells to TANs within the tumor was associated with anti-PD1 monotherapy failure in non-small cell lung cancer (NSCLC) patients, indicating that neutrophil antagonism may be a sustainable secondary therapeutic approach to boost ICI treatment outcomes (118). Here, CD8A is linked to non-small cell lung carcinoma.